ACHIEVE LIFE SCIENCES INC (ACHV)

ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023

ACHV stock results show that Achieve Life Sciences beat analyst estimates for earnings per share the fourth quarter of 2023.

ACHV Stock Earnings: Achieve Life Sciences Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Achieve Life Sciences (NASDAQ:ACHV) just reported results for the fourth quarte...

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024...

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Achieve Life Sciences stock falls 11% amid FDA update, securities sale (NASDAQ:ACHV)

Achieve Life Sciences (ACHV) stock fell 11% amid news it plans to conduct an additional clinical study for its drug cytisinicline and a securities offering worth up to $124.2M.

Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025...

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement

$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds...

Life Science Investor Forum: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Life Science Investor Forum Agenda Announced for December 14th, 2023

Wyndham Hotels (WH) Stock Pops on Takeover Offer

Wyndham Hotels stock is getting a boost on Tuesday following a takeover offer from Choice Hotels International for shares of WH.

LCID Stock Alert: Lucid Announces CFO Departure

Lucid stock is falling on Tuesday as investors in LCID react to the company's CFO departing immediately to pursue other opportunities.

Why Is Achieve Life Sciences (ACHV) Stock Down 25% Today?

Achieve Life Sciences stock is falling on Tuesday after the company provided ACHV investors with an FDA update concerning an NDA.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update

Company to host conference call at 4:30 PM EST today, Thursday, November 9, 2023...

Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023

SEATTLE and VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical...

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical...

Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Phase 2 ORCA-V1 trial results will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting, being held in London September 11–13, 2023.

Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update

Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE...

Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical...

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability” Supports...

Achieve Life Sciences stock down on pricing $16.5M stock offering (NASDAQ:ACHV)

Achieve Life Sciences (ACHV) shares are down 2.24% premarket on Thursday after the firm has entered into a securities purchase pact with certain institutional investors providing for...